...
xbio-img

Xenetic Biosciences Inc, Common Stock

XBIO

NASDAQ

$4.28

+$0.22

(5.42%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$6.26M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
28.19K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.26
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$2.78 L
$5.2 H
$4.28

About Xenetic Biosciences Inc, Common Stock

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies for hard to treat cancers. The company's proprietary DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments that targets pancreatic cancer comprising pancreatic ductal adenocarcinoma, colorectal carcinoma, and other gastrointestinal cancer. Its product pipeline includes XBIO-015 for treating pancreatic carcinoma and solid tumors; and XBIO-020 for treating solid tumors. The company also has partnered with biotechnology and pharmaceutical companies to develop its proprietary drug delivery platform, PolyXen, which as an enabling platform technology for protein and peptide drug delivery. It has collaboration agreements with Belgian Volition SARL Limited to develop NETs-targeted adoptive cell therapies for the treatment of cancer, as well as PJSC Pharmsynthez and Serum Institute of India to develop and launch ErepoXen for the treatment of anemia in chronic kidney disease patients; sublicensing agreement with Takeda Pharmaceutical Co. Ltd; exclusive sublicense agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase enzyme for use in treatment of cancer; and exclusive license agreement with CLS Therapeutics Ltd to develop and commercialize pharmaceutical products and methods incorporating DNase in conjunction with CAR T therapies. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameXBIOSectorS&P500
1-Week Return1.93%-3.35%-2.97%
1-Month Return9.74%-3.49%-0.66%
3-Month Return14.13%-12.6%2.71%
6-Month Return6.6%-6.91%7.21%
1-Year Return22.64%1.19%23.04%
3-Year Return-69.65%-0.21%28.43%
5-Year Return-70.48%33.09%82.88%
10-Year Return-99.38%93.55%184.63%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue17.07K436.94K1.16M1.71M2.54M[{"date":"2019-12-31","value":0.67,"profit":true},{"date":"2020-12-31","value":17.2,"profit":true},{"date":"2021-12-31","value":45.7,"profit":true},{"date":"2022-12-31","value":67.2,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue--35.48K27.04K-[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":76.22,"profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit17.07K436.94K1.13M1.68M2.54M[{"date":"2019-12-31","value":0.67,"profit":true},{"date":"2020-12-31","value":17.2,"profit":true},{"date":"2021-12-31","value":44.3,"profit":true},{"date":"2022-12-31","value":66.14,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin100.00%100.00%96.94%98.42%100.00%[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":96.94,"profit":true},{"date":"2022-12-31","value":98.42,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses9.62M5.13M6.91M8.42M7.06M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":53.34,"profit":true},{"date":"2021-12-31","value":71.8,"profit":true},{"date":"2022-12-31","value":87.57,"profit":true},{"date":"2023-12-31","value":73.34,"profit":true}]
Operating Income(12.89M)4.55M(5.75M)(6.72M)(4.52M)[{"date":"2019-12-31","value":-283.31,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-126.34,"profit":false},{"date":"2022-12-31","value":-147.69,"profit":false},{"date":"2023-12-31","value":-99.28,"profit":false}]
Total Non-Operating Income/Expense220.29K251.85K202.05K332.71K732.94K[{"date":"2019-12-31","value":30.06,"profit":true},{"date":"2020-12-31","value":34.36,"profit":true},{"date":"2021-12-31","value":27.57,"profit":true},{"date":"2022-12-31","value":45.39,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(12.78M)(13.81M)(5.65M)(6.55M)(4.13M)[{"date":"2019-12-31","value":-1277502500,"profit":false},{"date":"2020-12-31","value":-1381198400,"profit":false},{"date":"2021-12-31","value":-564517900,"profit":false},{"date":"2022-12-31","value":-655235300,"profit":false},{"date":"2023-12-31","value":-413457800,"profit":false}]
Income Taxes3.17M(2.92M)(100.47K)(165.56K)28.21K[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-91.93,"profit":false},{"date":"2021-12-31","value":-3.16,"profit":false},{"date":"2022-12-31","value":-5.21,"profit":false},{"date":"2023-12-31","value":0.89,"profit":true}]
Income After Taxes(15.95M)(10.89M)(5.54M)(6.39M)(4.16M)[{"date":"2019-12-31","value":-1594991500,"profit":false},{"date":"2020-12-31","value":-1089346600,"profit":false},{"date":"2021-12-31","value":-554471200,"profit":false},{"date":"2022-12-31","value":-638679800,"profit":false},{"date":"2023-12-31","value":-416278500,"profit":false}]
Income From Continuous Operations(12.78M)(10.89M)(5.65M)(6.55M)(4.45M)[{"date":"2019-12-31","value":-1277502500,"profit":false},{"date":"2020-12-31","value":-1089346600,"profit":false},{"date":"2021-12-31","value":-564517900,"profit":false},{"date":"2022-12-31","value":-655235300,"profit":false},{"date":"2023-12-31","value":-444560700,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(15.95M)(10.89M)(5.54M)(6.39M)(4.13M)[{"date":"2019-12-31","value":-1594991500,"profit":false},{"date":"2020-12-31","value":-1089346600,"profit":false},{"date":"2021-12-31","value":-554471200,"profit":false},{"date":"2022-12-31","value":-638679800,"profit":false},{"date":"2023-12-31","value":-413457800,"profit":false}]
EPS (Diluted)(3.39)(0.23)(0.55)(0.47)(2.75)[{"date":"2019-12-31","value":-339,"profit":false},{"date":"2020-12-31","value":-23,"profit":false},{"date":"2021-12-31","value":-55,"profit":false},{"date":"2022-12-31","value":-47,"profit":false},{"date":"2023-12-31","value":-275,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

XBIO
Cash Ratio 6.78
Current Ratio 6.96

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

XBIO
ROA (LTM) -28.74%
ROE (LTM) -48.61%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

XBIO
Debt Ratio Lower is generally better. Negative is bad. 0.13
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.87

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

XBIO
Trailing PE NM
Forward PE NM
P/S (TTM) 2.48
P/B 0.89
Price/FCF NM
EV/R 0.02
EV/Ebitda 1.03
PEG NM

FAQs

What is Xenetic Biosciences Inc share price today?

Xenetic Biosciences Inc (XBIO) share price today is $4.28

Can Indians buy Xenetic Biosciences Inc shares?

Yes, Indians can buy shares of Xenetic Biosciences Inc (XBIO) on Vested. To buy Xenetic Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in XBIO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Xenetic Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Xenetic Biosciences Inc (XBIO) via the Vested app. You can start investing in Xenetic Biosciences Inc (XBIO) with a minimum investment of $1.

How to invest in Xenetic Biosciences Inc shares from India?

You can invest in shares of Xenetic Biosciences Inc (XBIO) via Vested in three simple steps:

  • Click on Sign Up or Invest in XBIO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Xenetic Biosciences Inc shares
What is Xenetic Biosciences Inc 52-week high and low stock price?

The 52-week high price of Xenetic Biosciences Inc (XBIO) is $5.2. The 52-week low price of Xenetic Biosciences Inc (XBIO) is $2.78.

What is Xenetic Biosciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Xenetic Biosciences Inc (XBIO) is

What is Xenetic Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Xenetic Biosciences Inc (XBIO) is 0.89

What is Xenetic Biosciences Inc dividend yield?

The dividend yield of Xenetic Biosciences Inc (XBIO) is 0.00%

What is the Market Cap of Xenetic Biosciences Inc?

The market capitalization of Xenetic Biosciences Inc (XBIO) is $6.26M

What is Xenetic Biosciences Inc’s stock symbol?

The stock symbol (or ticker) of Xenetic Biosciences Inc is XBIO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top